Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consistent Minimal Manifestation Effect of Efgartigimod in generalized myasthenia gravis
jRCTs031260127Recruiting
- Sponsor
- argenx
- Start
- Sep 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of efgartigimod alfa and efgartigimod alfa + hyaluronidase-qvfc in myasthenia gravis (MG) (2 arms), sponsored by argenx. Primary endpoint: Proportion maintaining minimal manifestation status throughout observation period. Started Sep 2026; status: recruiting.
02
Drugs
efgartigimod alfaefgartigimod alfa + hyaluronidase-qvfc
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCTs031260127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260127.